SidaGhanaV1, PubMed, Corpus, bibRecord, 000573

Performance of Clinical Criteria for Screening of Possible Antiretroviral Related Mitochondrial Toxicity in HIV-Infected Children in Accra.

Identifieur interne : 000573 ( PubMed/Corpus ); précédent : 000572; suivant : 000574

Performance of Clinical Criteria for Screening of Possible Antiretroviral Related Mitochondrial Toxicity in HIV-Infected Children in Accra.

Auteurs : Allison Langs-Barlow ; Lorna Renner ; Karol Katz ; Veronika Northrup ; Elijah Paintsil

Source :

AIDS research and treatment [ 2090-1240 ] ; 2013.

RBID : pubmed:23533730

Abstract

Mitochondrial damage is implicated in highly active antiretroviral therapy (HAART) toxicity. HIV infection also causes mitochondrial toxicity (MT). Differentiating between the two is critical for HIV management. Our objective was to test the utility of the Mitochondrial Disease Criteria (MDC) and the Enquête Périnatale Française (EPF) to screen for possible HAART related MT in HIV-infected children in Ghana. The EPF and MDC are compilations of clinical symptoms, or criteria, of MT: a (+) score indicates possible MT. We applied these criteria retrospectively to 403 charts of HIV-infected children. Of those studied, 331/403 received HAART. Comparing HAART exposed and HAART naïve children, the difference in EPF score, but not MDC, approached significance (P = 0.1). Young age at HIV diagnosis or at HAART initiation was associated with (+) EPF (P ≤ 0.01). Adherence to HAART trended toward an association with (+) EPF (P = 0.09). Exposure to nevirapine, abacavir, or didanosine increased risk of (+) EPF (OR = 3.55 (CI = 1.99-6.33), 4.76 (2.39-9.43), 4.93 (1.29-18.87)). Neither EPF nor MDC identified a significant difference between HAART exposed or naïve children regarding possible MT. However, as indicators of HAART exposure are associated with (+) EPF, it may be a candidate for prospective study of possible HAART related MT in resource-poor settings.

DOI: 10.1155/2013/249171
PubMed: 23533730

Links to Exploration step

pubmed:23533730

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Performance of Clinical Criteria for Screening of Possible Antiretroviral Related Mitochondrial Toxicity in HIV-Infected Children in Accra.</title>
<author><name sortKey="Langs Barlow, Allison" sort="Langs Barlow, Allison" uniqKey="Langs Barlow A" first="Allison" last="Langs-Barlow">Allison Langs-Barlow</name>
<affiliation><nlm:affiliation>Department of Pediatrics, Yale School of Medicine, New Haven, CT 06520, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Renner, Lorna" sort="Renner, Lorna" uniqKey="Renner L" first="Lorna" last="Renner">Lorna Renner</name>
</author>
<author><name sortKey="Katz, Karol" sort="Katz, Karol" uniqKey="Katz K" first="Karol" last="Katz">Karol Katz</name>
</author>
<author><name sortKey="Northrup, Veronika" sort="Northrup, Veronika" uniqKey="Northrup V" first="Veronika" last="Northrup">Veronika Northrup</name>
</author>
<author><name sortKey="Paintsil, Elijah" sort="Paintsil, Elijah" uniqKey="Paintsil E" first="Elijah" last="Paintsil">Elijah Paintsil</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2013">2013</date>
<idno type="RBID">pubmed:23533730</idno>
<idno type="pmid">23533730</idno>
<idno type="doi">10.1155/2013/249171</idno>
<idno type="wicri:Area/PubMed/Corpus">000573</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000573</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Performance of Clinical Criteria for Screening of Possible Antiretroviral Related Mitochondrial Toxicity in HIV-Infected Children in Accra.</title>
<author><name sortKey="Langs Barlow, Allison" sort="Langs Barlow, Allison" uniqKey="Langs Barlow A" first="Allison" last="Langs-Barlow">Allison Langs-Barlow</name>
<affiliation><nlm:affiliation>Department of Pediatrics, Yale School of Medicine, New Haven, CT 06520, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Renner, Lorna" sort="Renner, Lorna" uniqKey="Renner L" first="Lorna" last="Renner">Lorna Renner</name>
</author>
<author><name sortKey="Katz, Karol" sort="Katz, Karol" uniqKey="Katz K" first="Karol" last="Katz">Karol Katz</name>
</author>
<author><name sortKey="Northrup, Veronika" sort="Northrup, Veronika" uniqKey="Northrup V" first="Veronika" last="Northrup">Veronika Northrup</name>
</author>
<author><name sortKey="Paintsil, Elijah" sort="Paintsil, Elijah" uniqKey="Paintsil E" first="Elijah" last="Paintsil">Elijah Paintsil</name>
</author>
</analytic>
<series><title level="j">AIDS research and treatment</title>
<idno type="ISSN">2090-1240</idno>
<imprint><date when="2013" type="published">2013</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Mitochondrial damage is implicated in highly active antiretroviral therapy (HAART) toxicity. HIV infection also causes mitochondrial toxicity (MT). Differentiating between the two is critical for HIV management. Our objective was to test the utility of the Mitochondrial Disease Criteria (MDC) and the Enquête Périnatale Française (EPF) to screen for possible HAART related MT in HIV-infected children in Ghana. The EPF and MDC are compilations of clinical symptoms, or criteria, of MT: a (+) score indicates possible MT. We applied these criteria retrospectively to 403 charts of HIV-infected children. Of those studied, 331/403 received HAART. Comparing HAART exposed and HAART naïve children, the difference in EPF score, but not MDC, approached significance (P = 0.1). Young age at HIV diagnosis or at HAART initiation was associated with (+) EPF (P ≤ 0.01). Adherence to HAART trended toward an association with (+) EPF (P = 0.09). Exposure to nevirapine, abacavir, or didanosine increased risk of (+) EPF (OR = 3.55 (CI = 1.99-6.33), 4.76 (2.39-9.43), 4.93 (1.29-18.87)). Neither EPF nor MDC identified a significant difference between HAART exposed or naïve children regarding possible MT. However, as indicators of HAART exposure are associated with (+) EPF, it may be a candidate for prospective study of possible HAART related MT in resource-poor settings.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">23533730</PMID>
<DateCreated><Year>2013</Year>
<Month>03</Month>
<Day>27</Day>
</DateCreated>
<DateCompleted><Year>2013</Year>
<Month>03</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised><Year>2017</Year>
<Month>02</Month>
<Day>20</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2090-1240</ISSN>
<JournalIssue CitedMedium="Print"><Volume>2013</Volume>
<PubDate><Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>AIDS research and treatment</Title>
<ISOAbbreviation>AIDS Res Treat</ISOAbbreviation>
</Journal>
<ArticleTitle>Performance of Clinical Criteria for Screening of Possible Antiretroviral Related Mitochondrial Toxicity in HIV-Infected Children in Accra.</ArticleTitle>
<Pagination><MedlinePgn>249171</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1155/2013/249171</ELocationID>
<Abstract><AbstractText>Mitochondrial damage is implicated in highly active antiretroviral therapy (HAART) toxicity. HIV infection also causes mitochondrial toxicity (MT). Differentiating between the two is critical for HIV management. Our objective was to test the utility of the Mitochondrial Disease Criteria (MDC) and the Enquête Périnatale Française (EPF) to screen for possible HAART related MT in HIV-infected children in Ghana. The EPF and MDC are compilations of clinical symptoms, or criteria, of MT: a (+) score indicates possible MT. We applied these criteria retrospectively to 403 charts of HIV-infected children. Of those studied, 331/403 received HAART. Comparing HAART exposed and HAART naïve children, the difference in EPF score, but not MDC, approached significance (P = 0.1). Young age at HIV diagnosis or at HAART initiation was associated with (+) EPF (P ≤ 0.01). Adherence to HAART trended toward an association with (+) EPF (P = 0.09). Exposure to nevirapine, abacavir, or didanosine increased risk of (+) EPF (OR = 3.55 (CI = 1.99-6.33), 4.76 (2.39-9.43), 4.93 (1.29-18.87)). Neither EPF nor MDC identified a significant difference between HAART exposed or naïve children regarding possible MT. However, as indicators of HAART exposure are associated with (+) EPF, it may be a candidate for prospective study of possible HAART related MT in resource-poor settings.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Langs-Barlow</LastName>
<ForeName>Allison</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Department of Pediatrics, Yale School of Medicine, New Haven, CT 06520, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Renner</LastName>
<ForeName>Lorna</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y"><LastName>Katz</LastName>
<ForeName>Karol</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y"><LastName>Northrup</LastName>
<ForeName>Veronika</ForeName>
<Initials>V</Initials>
</Author>
<Author ValidYN="Y"><LastName>Paintsil</LastName>
<ForeName>Elijah</ForeName>
<Initials>E</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>P30 MH062294</GrantID>
<Acronym>MH</Acronym>
<Agency>NIMH NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>T32 AI007210</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2013</Year>
<Month>03</Month>
<Day>07</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>AIDS Res Treat</MedlineTA>
<NlmUniqueID>101553816</NlmUniqueID>
<ISSNLinking>2090-1240</ISSNLinking>
</MedlineJournalInfo>
<CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2002 Mar 14;346(11):811-20</RefSource>
<PMID Version="1">11893792</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 2010 Jul 15;202(2):291-301</RefSource>
<PMID Version="1">20533872</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Annu Rev Med. 2010;61:169-85</RefSource>
<PMID Version="1">19622036</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Antivir Ther. 2003 Aug;8(4):333-8</RefSource>
<PMID Version="1">14526764</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Biol Regul Homeost Agents. 2002 Jan-Mar;16(1):18-24</RefSource>
<PMID Version="1">12003168</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>HIV Med. 2001 Jul;2(3):163-5</RefSource>
<PMID Version="1">11737396</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurology. 2002 Nov 12;59(9):1402-5</RefSource>
<PMID Version="1">12427891</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mol Pharmacol. 1991 May;39(5):625-8</RefSource>
<PMID Version="1">1851960</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>HIV Med. 2011 Nov;12(10):602-9</RefSource>
<PMID Version="1">21599820</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Acquir Immune Defic Syndr. 2009 Dec 1;52(4):443-51</RefSource>
<PMID Version="1">19779356</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>HIV Med. 2006 Jan;7(1):53-8</RefSource>
<PMID Version="1">16313293</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet. 1999 Sep 25;354(9184):1084-9</RefSource>
<PMID Version="1">10509500</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>AIDS. 2002 Mar 8;16(4):513-8</RefSource>
<PMID Version="1">11872993</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Antivir Ther. 2011;16(5):719-24</RefSource>
<PMID Version="1">21817193</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Crit Care. 2003 Jun;7(3):226-32</RefSource>
<PMID Version="1">12793872</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Ther. 2000 Aug;22(8):911-36; discussion 898</RefSource>
<PMID Version="1">10972629</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Acquir Immune Defic Syndr. 2012 Jun 1;60(2):111-6</RefSource>
<PMID Version="1">22362155</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Pediatr Infect Dis J. 2011 Nov;30(11):992-5</RefSource>
<PMID Version="1">21697766</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>JAMA. 2005 May 11;293(18):2213-20</RefSource>
<PMID Version="1">15886376</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Sex Transm Infect. 2001 Jun;77(3):158-73</RefSource>
<PMID Version="1">11402222</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Acquir Immune Defic Syndr. 2003 Sep;34 Suppl 1:S85-90</RefSource>
<PMID Version="1">14562863</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Med Virol. 2003 Aug;70(4):497-505</RefSource>
<PMID Version="1">12794710</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Infect Dis. 2004 Sep 1;39(5):710-6</RefSource>
<PMID Version="1">15356787</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Antimicrob Chemother. 2008 Jan;61(1):8-12</RefSource>
<PMID Version="1">17999978</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Infect Dis. 2004 Mar 1;38 Suppl 2:S73-9</RefSource>
<PMID Version="1">14986278</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cytometry B Clin Cytom. 2009 May;76(3):181-90</RefSource>
<PMID Version="1">18823003</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Pediatrics. 2007 Dec;120(6):1326-33</RefSource>
<PMID Version="1">18055683</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Acquir Immune Defic Syndr. 2002 Feb 1;29 Suppl 1:S28-40</RefSource>
<PMID Version="1">11832699</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>AIDS. 2007 May 11;21(8):929-38</RefSource>
<PMID Version="1">17457086</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<OtherID Source="NLM">PMC3606755</OtherID>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year>
<Month>12</Month>
<Day>12</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2013</Year>
<Month>01</Month>
<Day>31</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2013</Year>
<Month>02</Month>
<Day>11</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2013</Year>
<Month>3</Month>
<Day>28</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2013</Year>
<Month>3</Month>
<Day>28</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2013</Year>
<Month>3</Month>
<Day>28</Day>
<Hour>6</Hour>
<Minute>1</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">23533730</ArticleId>
<ArticleId IdType="doi">10.1155/2013/249171</ArticleId>
<ArticleId IdType="pmc">PMC3606755</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaGhanaV1/Data/PubMed/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000573 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000573 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    SidaGhanaV1
   |flux=    PubMed
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:23533730
   |texte=   Performance of Clinical Criteria for Screening of Possible Antiretroviral Related Mitochondrial Toxicity in HIV-Infected Children in Accra.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i   -Sk "pubmed:23533730" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a SidaGhanaV1

This area was generated with Dilib version V0.6.31.
Data generation: Tue Nov 7 18:07:38 2017. Site generation: Tue Mar 5 15:01:57 2024

	Le SIDA au Ghana (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Le SIDA au Ghana (serveur d'exploration)

Performance of Clinical Criteria for Screening of Possible Antiretroviral Related Mitochondrial Toxicity in HIV-Infected Children in Accra.

Performance of Clinical Criteria for Screening of Possible Antiretroviral Related Mitochondrial Toxicity in HIV-Infected Children in Accra.

Source :

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki